New Insights into Personalized Medicine for Ophthalmic Disease: From Mechanism to Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (5 November 2023) | Viewed by 135

Special Issue Editor

Pathophysiology Department, Universitatea de Medicina si Farmacie Iuliu Hatieganu din Cluj-Napoca, Cluj Napoca, Romania
Interests: nanomedicine; oxidative and nitrosative stress; inflammation; neuroophthalmology; ocular surface disorders mechanisms; retinal diseases mechanisms; nutraceuticals; translational medicine; personalized medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanotechnology continues to progress and to contribute to a modern approach towards patients from diagnosis methods to therapeutic options. The clinical applications and the molecular diagnosis in ophthalmology have been limited and the therapies are expected to be personalized. There is a high clinical need for new experimental efficient therapies to be implemented for patient benefits. There are real scientific progresses in mechanisms involved in the discovery of ocular surface disorders therapies, retinal disease pathology, glaucoma or neurooftalmology. Therapies with anti-vascular endothelial growth factor have resulted in enhanced outcomes for a variety of retinal disease such as age-related macular degeneration, retinal vascular obscruction, neovascular glaucoma, diabetes retinopathy or prematurity retinopathy. Cytoskeleton agents and prostaglandins can significantly improve the intraocular pressure control. Various molecular formulas eye drops therapies can alleviate the ocular surface disorders. Molecular mechanisms’ applications for personalized treatments can increase efficacy and improve the outcome in the majority of eye disease.

This Special Issue aims to focus on the latest research progress of the molecular bases of eye diseases and the relevant signalling pathways, as well as advanced techniques that help the diagnosis and in establishing personalized treatments. Authors are welcome to submit both articles and review papers.

Prof. Dr. Adriana Elena Bulboaca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • signaling pathways
  • eye diseases
  • oxidative stress in eye
  • nitrosative stress in eye
  • blood retinal barrier
  • blood–aqueous barrier
  • personalized medicine
  • nutraceuticals in eye diseases

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop